350 recruiting, 309 completed, 220 active not recruiting, 86 terminated. 451 Phase 2, 309 Phase 1, 246 Not applicable, 55 Phase 3, 27 Early Phase 1.
Follow Biopsy: new trials by email Literature Review of Biopsy trials Research Report on Biopsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Not yet recruiting | City of Hope Medical Center | 44 | 2027-08-04 | 2026-09-10 |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver | Phase 1 | Not yet recruiting | City of Hope Medical Center | 36 | 2027-05-06 | 2026-09-25 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma | Phase 2 | Not yet recruiting | Northwestern University | 56 | 2027-05-05 | 2026-10-07 |
| Incidence of HIV Infection in Screening Indian Men Who Have Sex With Men Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Medical Examination - HIV Infection | Withdrawn | AIDS Malignancy Consortium | 2027-04-30 | 2025-06-06 | ||
| Incidence of HPV Infection and HPV-Associated Disease in Screening Indian Men Who Have Sex With HIV-Positive Men Cytology Specimen Collection Procedure, High Resolution Anoscopy with Biopsy, Laboratory Biomarker Analysis - HIV Infection, Human Papillomavirus Infection | Withdrawn | AIDS Malignancy Consortium | 2027-04-30 | 2025-06-06 | ||
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Neuroblastoma | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 77 | 2027-04-09 | 2026-09-15 |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis Biopsy Procedure, Biospecimen Collection, Breast Conservation Treatment - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma | Phase 3 | Recruiting | SWOG Cancer Research Network | 562 | 2027-03-09 | 2026-10-13 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial Polatuzumab Vedotin, Acalabrutinib, Mosunetuzumab - Mantle Cell Lymphoma | Phase 2 | Not yet recruiting | University of Washington | 27 | 2027-03-01 | 2026-11-02 |
| Testing the Anti-cancer Drug DSP-5336 (Enzomenib) in Prostate Cancer Antiandrogen Therapy, Biopsy Procedure, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 24 | 2027-02-26 | 2026-11-12 |
| Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 35 | 2027-01-30 | 2026-11-05 |
| Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Azacitidine, Biospecimen Collection, Bone Marrow Aspiration - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 122 | 2027-01-15 | 2026-10-07 |
| Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Biopsy - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 244 | 2027-01-15 | 2026-10-20 |
| Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer Neoadjuvant Chemotherapy, Radiation Therapy, MRI - Breast Cancer, HER2-positive Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Ohio State University Comprehensive Cancer Center | 84 | 2027-01-15 | 2026-11-09 |
Showing 20 of 1181. Sign in to see all of them.
Breast Neoplasms (84) · Leukemia, Myeloid, Acute (62) · Prostatic Neoplasms (62) · Neoplasm Metastasis (58) · Melanoma (51) · Multiple Myeloma (48) · Colorectal Neoplasms (47) · Lung Neoplasms (43) · Pancreatic Neoplasms (42) · Carcinoma, Non-Small-Cell Lung (39) · Lymphoma (38) · Myelodysplastic Syndromes (36) · Leukemia, Lymphocytic, Chronic, B-Cell (33) · Neoplasms (30) · Squamous Cell Carcinoma of Head and Neck (30)
National Cancer Institute (NCI) (268) · Mayo Clinic (69) · City of Hope Medical Center (67) · Fred Hutchinson Cancer Center (31) · OHSU Knight Cancer Institute (27) · Children's Oncology Group (20) · Roswell Park Cancer Institute (20) · University of Washington (20) · M.D. Anderson Cancer Center (19) · Memorial Sloan Kettering Cancer Center (13) · Northwestern University (12) · Washington University School of Medicine (12) · Vanderbilt-Ingram Cancer Center (11) · Emory University (10) · Gustave Roussy, Cancer Campus, Grand Paris (9)
United States (808) · France (107) · Canada (75) · Puerto Rico (43) · United Kingdom (31) · China (26) · Australia (22) · Netherlands (22) · Germany (18) · Italy (18) · Spain (13) · Sweden (13) · Denmark (12) · New Zealand (10) · Belgium (9)
A P Chen (7) · Ibrahim Aldoss (7) · Curtis A Lachowiez (4) · Mengyang Di, MD, PhD (4) · Alexey V Danilov (3) · Amandeep Salhotra (3) · Cassian Yee (3) · David S Hong (3) · Geoffrey Shouse (3) · Grover C. Bagby, MD (3) · Haider S Mahdi (3) · Jennifer A Woyach, MD (3) · Joyce F Liu (3) · Matthew S. Block, MD, PhD (3) · Michael Schweizer (3)
PMID 41671463, PMID 35622074, PMID 32589970, PMID 35175355, PMID 42820295, PMID 10632519, PMID 10685537, PMID 10856474, PMID 14520092, PMID 15585733, PMID 15659033, PMID 15800894, PMID 16180217, PMID 16180227, PMID 16373758, PMID 17330838, PMID 17551310, PMID 17617273, PMID 18023439, PMID 18024211, PMID 18375408, PMID 18490686, PMID 18664475, PMID 18757332, PMID 19027770, PMID 19324990, PMID 19364967, PMID 19400928, PMID 19766264, PMID 19770804, PMID 19854029, PMID 19912985, PMID 19924284, PMID 20063546, PMID 20197669, PMID 20379145, PMID 20562526, PMID 20667781, PMID 20727190, PMID 20802024, PMID 20856865, PMID 20890283, PMID 20964826, PMID 21430075, PMID 21570352, PMID 21775417, PMID 21796368, PMID 21918674, PMID 21990404, PMID 22044694
P30CA033572 (65), U10CA180820 (42), U10CA180886 (29), UM1CA186689 (27), UM1CA186709 (24), U10CA180821 (21), U10CA180888 (19), UM1CA186691 (17), P30CA060553 (14), UM1CA186688 (14), U10CA180868 (12), UM1CA186644 (12), UM1CA186717 (12), UM1CA186712 (10), P30CA138292 (9)